BioMarin Pharmaceutical, Inc. (BMRN)
64.88
-0.35
(-0.54%)
USD |
NASDAQ |
Sep 01, 16:00
64.88
0.00 (0.00%)
After-Hours: 20:00
BioMarin Pharmaceutical Research and Development Expense (Annual) : 700.97M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 700.97M |
| December 31, 2024 | 747.18M |
| December 31, 2023 | 746.77M |
| December 31, 2022 | 649.61M |
| December 31, 2021 | 628.79M |
| December 31, 2020 | 628.12M |
| December 31, 2019 | 715.01M |
| December 31, 2018 | 696.33M |
| December 31, 2017 | 610.75M |
| December 31, 2016 | 661.90M |
| December 31, 2015 | 634.81M |
| December 31, 2014 | 467.64M |
| December 31, 2013 | 354.78M |
| December 31, 2012 | 302.22M |
| December 31, 2011 | 214.37M |
| Date | Value |
|---|---|
| December 31, 2010 | 147.31M |
| December 31, 2009 | 115.12M |
| December 31, 2008 | 93.29M |
| December 31, 2007 | 78.60M |
| December 31, 2006 | 66.74M |
| December 31, 2005 | 56.39M |
| December 31, 2004 | 49.78M |
| December 31, 2003 | 54.81M |
| December 31, 2002 | 54.46M |
| December 31, 2001 | 45.28M |
| December 31, 2000 | 35.79M |
| December 31, 1999 | 27.21M |
| December 31, 1998 | 10.50M |
| December 31, 1997 | 1.914M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Incyte Corp. | 1.984B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| BridgeBio Pharma, Inc. | 451.95M |
| Ionis Pharmaceuticals, Inc. | 913.18M |